相似文献
1
VKORC1 polymorphisms and complete resistance to vitamin K antagonists: About two cases.维生素K环氧化物还原酶复合体亚单位1（VKORC1）基因多态性与对维生素K拮抗剂完全耐药：两例报告
Biomedicine (Taipei). 2024 Mar 1;14(1):60-63. doi: 10.37796/2211-8039.1434. eCollection 2024.
2
VKORC1 polymorphisms and warfarin maintenance dose in population of Sakha (Yakuts).萨哈（雅库特）人群中维生素K环氧化物还原酶复合体亚单位1（VKORC1）基因多态性与华法林维持剂量
Int J Risk Saf Med. 2015;27 Suppl 1:S17-8. doi: 10.3233/JRS-150673.
3
VKORC1 and CYP2C9 genotypes in Egyptian patients with warfarin resistance.埃及华法林抵抗患者的维生素K环氧化物还原酶复合体亚单位1（VKORC1）和细胞色素P450 2C9（CYP2C9）基因型
Blood Coagul Fibrinolysis. 2016 Mar;27(2):121-6. doi: 10.1097/MBC.0000000000000168.
4
Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes.维生素 K 拮抗剂在 VKORC1 和 CYP2C9 基因型中的给药算法。
J Thromb Haemost. 2017 Mar;15(3):465-472. doi: 10.1111/jth.13615. Epub 2017 Feb 17.
5
In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes.在儿科患者中，年龄对维生素 K 拮抗剂的剂量影响大于 VKORC1 或 CYP2C9 基因型。
Blood. 2010 Dec 23;116(26):6101-5. doi: 10.1182/blood-2010-05-283861. Epub 2010 Sep 10.
6
VKORC1 mutations detected in patients resistant to vitamin K antagonists are not all associated with a resistant VKOR activity.在对维生素 K 拮抗剂有耐药性的患者中检测到的 VKORC1 突变并非都与 VKOR 活性的耐药性有关。
J Thromb Haemost. 2012 Dec;10(12):2535-43. doi: 10.1111/jth.12019.
7
A vitamin K epoxide reductase-oxidase complex gene polymorphism (-1639G>A) and interindividual variability in the dose-effect of vitamin K antagonists.维生素 K 环氧化物还原酶-氧化酶复合物基因多态性（-1639G>A）与维生素 K 拮抗剂剂量效应的个体间变异性。
J Appl Genet. 2009;50(4):399-403. doi: 10.1007/BF03195700.
8
9
Impact of VKORC1 gene polymorphisms on warfarin maintenance dosage: A novel systematic review and meta-analysis of 53 studies.维生素K环氧化物还原酶复合体亚单位1（VKORC1）基因多态性对华法林维持剂量的影响：对53项研究的一项新的系统评价和荟萃分析
Int J Clin Pharmacol Ther. 2017 Apr;55(4):304-321. doi: 10.5414/CP202833.
10
The Influence of VKORC1 Polymorphisms on Warfarin Doses in Thai Patients with Deep Vein Thrombosis.VKORC1基因多态性对泰国深静脉血栓患者华法林剂量的影响
J Med Assoc Thai. 2015 Jun;98(6):549-54.
本文引用的文献
1
A genome-wide CRISPR-Cas9 knockout screen identifies FSP1 as the warfarin-resistant vitamin K reductase.全基因组 CRISPR-Cas9 敲除筛选鉴定 FSP1 为华法林耐药性维生素 K 还原酶。
Nat Commun. 2023 Feb 14;14(1):828. doi: 10.1038/s41467-023-36446-8.
2
Factor XI/XIa Inhibition: The Arsenal in Development for a New Therapeutic Target in Cardio- and Cerebrovascular Disease.因子XI/XIa抑制：心血管和脑血管疾病新治疗靶点的研发武器库。
J Cardiovasc Dev Dis. 2022 Dec 6;9(12):437. doi: 10.3390/jcdd9120437.
3
Thrombophilia testing: A British Society for Haematology guideline.血栓形成倾向检测：英国血液学学会指南
Br J Haematol. 2022 Aug;198(3):443-458. doi: 10.1111/bjh.18239. Epub 2022 May 29.
4
The Role of Pharmacogenetics in Antithrombotic Therapy Management: New Achievements and Barriers Yet to Overcome.药物遗传学在抗血栓治疗管理中的作用：新成就与尚待克服的障碍
Curr Med Chem. 2021;28(32):6675-6703. doi: 10.2174/0929867328666201231124715.
5
A novel vitamin K derived anticoagulant tolerant to genetic variations of vitamin K epoxide reductase.一种对维生素K环氧化物还原酶基因变异具有耐受性的新型维生素K衍生抗凝剂。
J Thromb Haemost. 2021 Mar;19(3):689-700. doi: 10.1111/jth.15209. Epub 2021 Jan 22.
6
Genetic Warfarin-Resistance Resulting in Surgery to Change a Prosthetic Valve.导致为更换人工瓣膜而进行手术的遗传性华法林抵抗。
Eur J Case Rep Intern Med. 2020 Aug 5;7(11):001851. doi: 10.12890/2020_001851. eCollection 2020.
7
American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.美国血液学会2020年静脉血栓栓塞管理指南：深静脉血栓形成和肺栓塞的治疗
Blood Adv. 2020 Oct 13;4(19):4693-4738. doi: 10.1182/bloodadvances.2020001830.
8
Prevention of Venous Thromboembolism in 2020 and Beyond.2020年及以后静脉血栓栓塞的预防
J Clin Med. 2020 Aug 1;9(8):2467. doi: 10.3390/jcm9082467.
9
Genotype-guided warfarin dosing may benefit patients with mechanical aortic valve replacements: randomized controlled study.基因指导的华法林剂量可能使机械主动脉瓣置换患者受益：随机对照研究。
Sci Rep. 2020 Apr 24;10(1):6988. doi: 10.1038/s41598-020-63985-7.
10
Genetic causes of resistance to vitamin K antagonists in Polish patients: a novel p.Ile123Met mutation in VKORC1 gene.波兰患者中维生素K拮抗剂抵抗的遗传原因：VKORC1基因中的一种新型p.Ile123Met突变
Blood Coagul Fibrinolysis. 2018 Jul;29(5):429-434. doi: 10.1097/MBC.0000000000000737.
Zotero 插件